Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC26A3 | P40879 | 10/20 | 0.77 |
| ▸ | MEN1 | O00255 | 2/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24045265 | 0.89 | SLC26A3 (0.81) | SLC26A3MEN1KMT2A | |
| SCHEMBL30154899 | 0.87 | SLC26A3 (1.00) | SLC26A3MEN1KMT2A | |
| SCHEMBL26687589 | 0.87 | SLC26A3 (1.00) | SLC26A3MEN1KMT2A | |
| SCHEMBL24045264 | 0.87 | SLC26A3 (0.79) | SLC26A3MEN1KMT2A | |
| SCHEMBL24045105 | 0.87 | SLC26A3 (1.00) | SLC26A3MEN1KMT2A | |
| SCHEMBL24045268 | 0.87 | SLC26A3 (0.79) | SLC26A3 | |
| SCHEMBL26687628 | 0.86 | SLC26A3 (0.73) | SLC26A3MEN1KMT2A | |
| SCHEMBL2843238 | 0.85 | SLC26A3 (0.72) | SLC26A3MEN1KMT2A | |
| SCHEMBL24045106 | 0.85 | SLC26A3 (1.00) | SLC26A3 | |
| SCHEMBL24045333 | 0.84 | SLC26A3 (0.73) | SLC26A3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130171158-A1 | TREATMENT OF ABNORMALITIES OF GLUCOSE METABOLISM WITH AN ANTAGONIST OF INHIBITOR OF DIFFERENTIATION 1 | GARVAN INSTITUTE OF MEDICAL RESEARCH (AU) | 2013-07-04 | — | — | US | claimed |
| WO-2012000036-A1 | TREATMENT OF ABNORMALITIES OF GLUCOSE METABOLISM WITH AN ANTAGONIST OF INHIBITOR OF DIFFERENTIATION 1 | GARVAN INSTITUTE OF MEDICAL RESEARCH (AU) | 2012-01-05 | — | — | WO | claimed |
| US-20230339878-A1 | SLC26A3 INHIBITORS AND USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-10-26 | — | — | US | disclosed |
| US-11591304-B2 | SLC26A3 inhibitors and use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-02-28 | — | — | US | disclosed |
| US-20210363123-A1 | SLC26A3 INHIBITORS AND USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-11-25 | — | — | US | disclosed |
| US-20130171158-A1 | TREATMENT OF ABNORMALITIES OF GLUCOSE METABOLISM WITH AN ANTAGONIST OF INHIBITOR OF DIFFERENTIATION 1 | GARVAN INSTITUTE OF MEDICAL RESEARCH (AU) | 2013-07-04 | — | — | US | disclosed |
| US-8138356-B2 | Chemical inhibitors of inhibitors of differentiation | Angiogeney, Inc. (US) | 2012-03-20 | — | — | US | disclosed |
| WO-2012000036-A1 | TREATMENT OF ABNORMALITIES OF GLUCOSE METABOLISM WITH AN ANTAGONIST OF INHIBITOR OF DIFFERENTIATION 1 | GARVAN INSTITUTE OF MEDICAL RESEARCH (AU) | 2012-01-05 | — | — | WO | disclosed |
| US-20090226422-A1 | Chemical Inhibitors of Inhibitors of Differentiation | ANGIOGENEX | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339878-A1 | SLC26A3 INHIBITORS AND USE THEREOF | SLC26A3, SLC10A2, SLC10A6 | SLC26A3 1/4885MEN1 4700/4885KMT2A 4380/4885 |
| US-20210363123-A1 | SLC26A3 INHIBITORS AND USE THEREOF | SLC26A3, SLC10A2, SLC10A6 | SLC26A3 1/4885MEN1 4646/4885KMT2A 4076/4885 |
| US-11591304-B2 | SLC26A3 inhibitors and use thereof | SLC26A3, SLC10A2, SLC10A6 | SLC26A3 1/4885MEN1 4646/4885KMT2A 4076/4885 |
| US-20130171158-A1 | TREATMENT OF ABNORMALITIES OF GLUCOSE METABOLISM WITH AN ANTAGONIST OF INHIBITOR OF DIFFERENTIATION 1 | FBP1, G6PC1, G6PD | SLC26A3 3042/4885MEN1 1240/4885KMT2A 2367/4885 |
| US-20090226422-A1 | Chemical Inhibitors of Inhibitors of Differentiation | BRAF, MAPK1, RAF1 | SLC26A3 4118/4885MEN1 3968/4885KMT2A 3273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.